Here is a nice piece of PR trying to capitalize on Viagra's risk profile, too bad it's not VVUS doing it.
Move Over Viagra! New Safe Alternative Leading The Way!
LOS ANGELES--(BW HealthWire)--Feb. 17, 1999--Erogen recently released its Erogenex male formula and Erogenex female formulas (also known by their formula name, Ex22). Erogen claims the capsules not only enhance sexual performance, but can also increase libido. Although the pills are not yet being formally marketed, sales are through the roof and Erogenex has already caught the eyes of many distributors overseas. A company spokesperson says that while nothing has yet been finalized, negotiations to export are underway with large companies in Europe as well as Asia. Erogen does have plans to actively begin marketing Erogenex over the next two months.
The overwhelming response so far to the Erogenex products with no formal marketing endeavors by the company, seems to be a good sign of future revenues. Company spokesperson Sandra Lock says, "It is not hard to see why a product such as Erogenex would make such a huge impact. The fact is that Erogenex is a safe product based on twenty years of research and clinical testing." She goes on to say, "People are clamoring to try this product in hopes that it will work for them. There are no negative side effects associated with Erogenex, and it is a fraction of the cost of its 'prescription-only counterparts.'" She points out that the product has about a 77% success rate in men and the success rate for women is slightly less; but in most cases all experience some positive benefits. The product does come with a thirty day money back guarantee, so it seems one would have little or nothing to lose in trying Erogenex.
Erogen has tapped in to a market that seemed destined to be cornered by the likes of Pfizer (PFE) and Zonagen (Nasdaq:ZONA). But Icos Corp (Nasdaq:ICOS), Tap Holdings, and Bio Technology General (Nasdaq:BTGC) are all working on rival treatments and Pentech Pharmaceuticals of Wheeling III has a drug in late-stage testing. Indianapolis-based Eli Lilly (NYSE:LLY) and New York-based Bristol-Myers Squibb Co. (NYSE:BMY) are also looking to make drugs from scratch through partnerships or from drugs now slated for other uses.
Amongst all of the rising competition are rising health concerns. Red flags have been raised due to the over one hundred fatalities linked to the use of Viagra. These health concerns associated with Viagra, and side effects linked to the other prescription-only formulas, have actually aided Erogen in tapping in to an enormous segment of the market. The non-prescription Erogenex seems to be a smart alternative for those seeking help with sexual performance but who are concerned with prescription formulas and their side effects. |
